ANGPTL3 use of antagonists for the treatment of liver diseases

Use of an antagonist of Angptl3 in the manufacture of a medicament for treating or preventing danotisular associated with an inflammatory liver disease characterized by excessive expression of Angptl3, wherein the antagonist Angptl3 joins Angptl3 or integrin αvs3 and it inhibits the ability of Angptl3 paraunirse specifically to and regulate cellular responses mediated by integrin αvs3, and wherein elantagonista is: a) an antibody, wherein the antibody is an antibody directed against Angptl3 or an antibody directed against αvβ3 laintegrina; b) an immunoadhesin, wherein the immunoadhesin comprising the ligand binding region of αvβ3fusionada integrin with an immunoglobulin sequence or the receptor binding region fused with unasecuencia Angptl3 immunoglobulin; c) a combination of a peptide comprising SEQ ID NO: 14, a peptide comprising SEQ ID NO: 15 yun peptide comprising SEQ ID NO: 17.